AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
- Innovative Gene-Targeting Approach: Roquefort’s STAT-6 siRNA programme targets inflammation and immune response at the genetic level.
- Promising Reductions in Inflammatory Markers: Data show a tenfold decrease in STAT-6 protein and reductions in associated immune indicators.
- Potential Competitive Edge in STAT-6 Research: Early findings suggest Roquefort’s siRNA approach could outperform other leading STAT-6 therapies.
Roquefort Therapeutics PLC (LSE:ROQ), a biopharmaceutical company specializing in genetic-based treatments for immunology and oncology, is poised to unveil new insights from its STAT-6 siRNA programme at the Advanced Therapy Development Congress in London. This innovative research targets inflammation and immune-related diseases by focusing on small interfering RNA (siRNA) technology, a precise approach that reduces gene activity to control cellular processes.
Roquefort’s research zeroes in on the STAT-6 protein, a key player in immune signalling pathways that contribute to Type 2 inflammation—a factor implicated in chronic diseases like asthma and severe allergies. STAT-6’s involvement in overactive immune cell signalling makes it an attractive target for therapies aimed at reining in harmful inflammation. By blocking STAT-6 at the genetic level, Roquefort aims to address diseases rooted in immune dysregulation, a growing area of therapeutic development.
Recent laboratory data from Roquefort's programme demonstrated a striking tenfold reduction in STAT-6 protein levels alongside significant decreases in related inflammatory markers. These promising findings underscore the potential of Roquefort’s STAT-6 siRNA to effectively manage immune-driven conditions by targeting the genetic drivers of inflammation. The data build on previous results from Roquefort’s oncology research and highlight the company’s strength in gene-targeting technology as it expands into the field of immunology.
CEO Ajan Reginald emphasized the company’s approach: “The results presented today highlight the company's internal research and development expertise in the Immunology and Inflammation field and the potency of our siRNA program, in the highly attractive STAT-6 niche.” With advice from industry partners, Roquefort designed its research strategy to align closely with the needs of potential pharmaceutical collaborators, positioning the company to deliver siRNA solutions that stand out in competitive head-to-head comparisons with other STAT-6 therapies.
Roquefort’s continued advancements reflect the increasing validation of gene-targeted therapies in immunology and underscore the rising industry interest in STAT-6 as a promising therapeutic target. The company’s latest findings suggest that its siRNA approach not only meets but may surpass the efficacy of existing STAT-6-focused treatments, positioning Roquefort as a strong player in the development of next-generation therapies for immune-related diseases.
